X0508 4 2026-01-02 0001133416 GALECTIN THERAPEUTICS INC GALT 0001266773 CALLICUTT JACK W C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS GA 30071 false true false false Chief Financial Officer true Common Stock 2026-01-02 4 M false 60000 0 A 67614 D Common Stock 2026-01-02 4 S false 13914 4.1968 D 53700 D Common Stock 2026-01-05 4 S false 25732 3.8978 D 27968 D Common Stock 2026-01-06 4 S false 20354 3.6698 D 7614 D Restricted Stock Unit 0 2026-01-01 4 M false 60000 0 D 2026-01-02 Common Stock 60000 0 D The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Jack W. Callicutt 2026-01-06